



## Monthly information on share capital and company voting rights

(Article 223-16 of General Regulation of the French financial markets authority)

Listing market: NYSE Euronext Paris

ISIN code: FR0010425595

Date	Total number of shares in the capital	Total number of voting rights
02/28/2018	35,959,462	41,113,840

### About Cellecctis

Cellecctis is a clinical-stage biopharmaceutical company focused on developing a new generation of cancer immunotherapies based on gene-edited T-cells (UCART). By capitalizing on its 18 years of expertise in gene editing – built on its flagship TALEN® technology and pioneering electroporation system PulseAgile – Cellecctis uses the power of the immune system to target and eradicate cancer cells.

Using its life-science-focused, pioneering genome engineering technologies, Cellecctis' goal is to create innovative products in multiple fields and with various target markets. Cellecctis is listed on the Nasdaq market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS). To find out more about us, visit our website: [www.cellecctis.com](http://www.cellecctis.com)

Talking about gene editing? We do it. TALEN® is a registered trademark owned by the Cellecctis Group.

### For further information, please contact:

#### Media contacts:

Jennifer Moore, VP of Communications, 917-580-1088, [media@cellectis.com](mailto:media@cellectis.com)  
Caitlin Kasunich, KCSA Strategic Communications, 212-896-1241, [ckasunich@kcsa.com](mailto:ckasunich@kcsa.com)

#### IR contact:

Simon Harnest, VP of Corporate Strategy and Finance, 646-385-9008, [simon.harnest@cellectis.com](mailto:simon.harnest@cellectis.com)

#### Disclaimer

This press release contains “forward-looking” statements that are based on our management’s current expectations and assumptions and on information currently

available to management. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Further information on the risks factors that may affect company business and financial performance, is included in filings Collectis makes with the Security Exchange Commission from time to time and its financial reports. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.

###